Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542


Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

Press Release

Medtech Market to Achieve Global Sales of $514 Billion by 2020; Megamergers Set to Reshuffle Top Players

Evaluate's third annual sector report provides exclusive consensus forecasts to 2020

Download PDF

LONDON, BOSTON, TOKYO (October 6, 2014) — The medical technology sector is expected to grow at a compound annual growth rate of 5 percent per year between 2013 and 2020, according to the latest forecasts from market intelligence firm Evaluate Ltd. Its new report, “EvaluateMedTech World Preview 2014, Outlook to 2020,” released today at the AdvaMed 2014 conference in Chicago, reveals that global medtech sales are expected to reach $514 billion by 2020, with megamergers reshaping the lineup of industry leaders. 

Looking at recent industry activity, the report shows that the value of completed medtech M&A deals jumped 363 percent during the first half of 2014 compared with the same period in 2013. M&A activity will continue on a large scale; when Medtronic and Covidien join forces next year, the $42.9 billion deal will mark the single biggest merger in the sector’s history. Likewise, the $13.4 billion merger between orthopedic powerhouses Zimmer and Biomet, also set to close in 2015, will have profound changes for the orthopedic segment of the market.

“2014 marks a year of rapid change for the global medical device market, particularly within the cardiology and orthopedic spaces, which have been dominated by megamergers,” said Ian Strickland, report author and EvaluateMedTech Product Manager. “If the deal between Covidien and Medtronic goes through, we could see a new market leader. In an industry forecast to be worth more than half a trillion dollars in 2020, that is no insignificant achievement.”

Among the report’s key findings:

  • Worldwide medtech sales are forecast to reach $514 billion by 2020
  • Global R&D spend is set to grow by 4.2 percent (CAGR) to $30.5 billion by 2020
  • FDA granted 23 first-time premarket approvals of medical devices in 2013, compared with 41 in 2012 - a massive 44 percent decrease
  • M&A deal value in the medtech sector jumped 363 percent to $30 billion in the first half of 2014 over the same period in 2013
  • $1.3 billion raised in completed medtech IPOs during the first half of 2014, 44 percent more than the whole of 2013

Based on EvaluateMedTech’s coverage of the global medtech sector, the World Preview highlights trends in medtech including: consensus sales forecasts to 2020, the top 20 companies in 2020, R&D spending currently and in the future, FDA approvals, M&A activity, venture financing, IPOs and enterprise value. To download the full complimentary report and infographic visit: www.evaluategroup.com/MedTechWP2014. A hard-copy Executive Summary of the report is available at EvaluateMedTech’s Booth #111 at AdvaMed 2014: The MedTech Conference, being held in Chicago Oct. 6-8.

About Evaluate Ltd.
Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2020. We support life science and healthcare companies, financial institutions, consultancies and service providers in their strategic decision-making. Our services include EvaluatePharma, EvaluateClinical Trials and EvaluateMedTech. Our global team of dedicated healthcare analysts employs rigorous methodologies to deliver strategic commercial analysis. We make our services valuable by combining superior quality content, user-friendly reporting tools and outstanding customer service to solve client problems.

For more information visit: www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @epclinicaltrial, @epvantage.

Back to Press Releases